| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.07. | HeartBeam receives patent for multi-modal cardiac sensing device | 1 | Investing.com | ||
| 02.07. | HeartBeam, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.06. | HeartBeam, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.05. | H.C. Wainwright cuts Heartbeam stock price target on slower sales ramp | 1 | Investing.com | ||
| 15.05. | Benchmark cuts Heartbeam stock price target on dilution to $5 | 1 | Investing.com | ||
| 13.05. | Earnings Call: HeartBeam übertrifft EPS-Prognose für Q1 2026 - Aktie legt nachbörslich zu | 2 | Investing.com Deutsch | ||
| 13.05. | HeartBeam Q1 2026 Earnings Call: Complete Transcript | 4 | Benzinga.com | ||
| HEARTBEAM Aktie jetzt für 0€ handeln | |||||
| 13.05. | HeartBeam GAAP EPS of -$0.12 beats by $0.02 | 1 | Seeking Alpha | ||
| 13.05. | HeartBeam, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 11.05. | HeartBeam starts pilot study of on-demand 12-lead ECG patch | - | MassDevice | ||
| 24.04. | HeartBeam (BEAT): 10 Best NASDAQ Growth Stocks to Buy and Hold Forever | 16 | Insider Monkey | ||
| 20.04. | Heartbeam: D. Boral Capital stuft Aktie wegen Konditionen der Kapitalerhöhung herab | 16 | Investing.com Deutsch | ||
| 20.04. | D. Boral Capital cuts Heartbeam stock rating on capital raise terms | 1 | Investing.com | ||
| 16.04. | HeartBeam closes $10M public offering for product rollout | 1 | Investing.com | ||
| 16.04. | HeartBeam, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.04. | HeartBeam slips 12%, prices $10M stock offering | 4 | Seeking Alpha | ||
| 15.04. | HeartBeam prices $10M public offering at $0.80 per share | 1 | Investing.com | ||
| 14.04. | HeartBeam announces stock offering; shares drop 18% after-hours | 1 | Seeking Alpha | ||
| 14.04. | HeartBeam kündigt öffentliches Angebot von Stammaktien an | 1 | Investing.com Deutsch | ||
| 14.04. | HeartBeam launches public offering of common stock | 1 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 13,900 | +2,21 % | Eckert & Ziegler: Was die BaFin jetzt untersucht | ||
| UNITEDHEALTH | 352,40 | +0,06 % | UnitedHealth-Aktie: Bullischer Konter voraus? | Die UnitedHealth-Aktie könnte nach dem jüngsten Rücksetzer vor einem neuen bullischen Konter stehen. Im Bereich zwischen 399,65 und 404,15 US$ trifft der Titel auf eine wichtige Unterstützungszone,... ► Artikel lesen | |
| THERMO FISHER | 510,60 | -0,58 % | Thermo Fisher-Aktie +9%: Was darf man sich vom Life-Science-Riesen erwarten? | Der Kurs der Thermo Fisher Scientic-Aktie legte gestern um fast +9% zu und setzte damit die positive Kursentwicklung der letzten Wochen fort. Was steckt hinter der guten Performance des US-Laborausrüsters... ► Artikel lesen | |
| DEXCOM | 72,60 | -1,09 % | Insulet sends Tandem, DexCom lower after guidance cut | ||
| RESMED | 182,25 | -0,63 % | Resmed Inc Announces Increase In Q4 Income | WASHINGTON (dpa-AFX) - Resmed Inc (RMD.AX) reported a profit for its fourth quarter that Increases, from the same period last yearThe company's earnings came in at $383.432 million, or $2.64... ► Artikel lesen | |
| HEALWELL AI | 0,420 | +0,12 % | HEALWELL AI kündigt Telefonkonferenz zur Erörterung der Finanzergebnisse des zweiten Quartals 2026 für den 7. August 2026 an | HEALWELL AI wird am Freitag, den 7. August 2026, um 8:30 Uhr ET (5:30 Uhr PT) eine Telefonkonferenz und einen gleichzeitigen Webcast
abhalten
TORONTO, ON, 4. August 2026... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,020 | -1,94 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| LIFEWARD | 7,200 | -6,13 % | Lifeward Out With Q2 Numbers | ||
| IMUNON | 1,380 | 0,00 % | Imunon Q2 2026 Earnings Preview | ||
| INSPIRE MEDICAL SYSTEMS | 51,50 | -1,90 % | Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan | Generated second quarter revenue of $200.6 millionSecond quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14Second quarter operating cash flow of $23.2 millionAnnounced strategic growth plan... ► Artikel lesen | |
| INSPIREMD | 0,635 | -1,55 % | InspireMD Inc.: InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| GT BIOPHARMA | 0,320 | 0,00 % | GT Biopharma, Inc.: GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors | GTB-5550 is now the 3rd TriKE- to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation... ► Artikel lesen | |
| MYOMO | 1,248 | +1,30 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M | ||
| INOGEN | 5,950 | +13,33 % | Inogen Inc - 10-Q, Quarterly Report | ||
| INTELLIGENT BIO SOLUTIONS | 1,990 | +0,51 % | Intelligent Bio Solutions, Inc.: Intelligent Bio Solutions Completes Usability Study Supporting FDA 510(k) Submission | NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing... ► Artikel lesen |